Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20–44 years of age

Effect of Depo-Medroxyprogesterone Acetate on Breast Cancer Risk among Women 20 to 44 Years of Age

(2012) C. I. Li et al.   CANCER RESEARCH

Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger

(2011) Mia M. Gaudet et al.   BREAST CANCER RESEARCH AND TREATMENT

Body Size, Physical Activity, and Risk of Triple-Negative and Estrogen Receptor-Positive Breast Cancer

(2011) A. I. Phipps et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Reproductive History and Oral Contraceptive Use in Relation to Risk of Triple-Negative Breast Cancer

(2011) A. I. Phipps et al.   JNCI-Journal of the National Cancer Institute

Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk

(2010) Amanda I. Phipps et al.   BREAST CANCER RESEARCH AND TREATMENT

Higher parity and shorter breastfeeding duration

(2010) Shivani S. Shinde et al.   CANCER

Use of Four Biomarkers to Evaluate the Risk of Breast Cancer Subtypes in the Women's Contraceptive and Reproductive Experiences Study

(2010) H. Ma et al.   CANCER RESEARCH

The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: The California Cancer Registry, 1999–2004

(2008) Monica Brown et al.   CANCER

High prevalence of triple-negative tumors in an urban cancer center

(2008) Mary Jo B. Lund et al.   CANCER

Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer

(2008) Amanda I. Phipps et al.   CANCER

Body Size and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer in Postmenopausal Women

(2008) A. I. Phipps et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION